Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research

Streetwise Reports, Streetwise Reports
0 Comments| December 12, 2019

{{labelSign}}  Favorites

Proteostasis Therapeutics' shares traded higher today after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021.


This morning, clinical-stage biopharmaceutical company Proteostasis Therapeutics Inc. (PTI:NASDAQ), which is focused on the discovery and development of therapies to treat cystic fibrosis (CF), announced "positive, initial ex-vivo results of PTI's proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators, PTI-801, PTI-808 and PTI-428, in individuals with CF who are ineligible for the current standard of care CFTR modulator therapies due to their genotype. The data are part of a pan-European strategic initiative, known as HIT-CF (Human Individualized Therapy of CF)."

The HIT-CF Europe research project's goal is to provide better treatment and improve the lives of people with CF and rare mutations. In the project, drug candidates are first tested on patient-derived organoids in qualified laboratories across Europe that are part of the European Cystic Fibrosis Society Clinical Trial Network. Based on the test results, a smaller group of patients will be invited to participate in a clinical trial with one or more investigational molecules from a participating pharmaceutical company.

The company explains in the report that organoids are cell cultures made from stem cells that grow in a culture dish and look similar to the organ from which they are derived. The firm advised that investigational drugs that target the basic defect of CF may have a positive effect and can be used in an organoid system to evaluate rare mutations.

According to the report, "rectal organoids from over 300 subjects have been collected for functional profiling and of those, 65 have been tested for response to PTI's investigational drugs. Early results support the initiation of enrollment of responding subjects into HIT-CF's clinical trial known as CHOICES, which is designed to evaluate the translation of organoid ex-vivo response to potential clinical benefit." The CHOICES study is expected to commence in mid-2020 with initial data findings expected by year-end 2020. The firm noted that the trial will be the first ever personalized medicine-based study in CF. The firm is optimistic that the results may serve as the basis for a potential Marketing Authorization Application with the European Medicines Agency in 2021.

The company's Chief Medical Officer Geoffrey Gilmartin, M.D., M.M.Sc., commented, "Proteostasis is honored to have been invited to participate in the HIT-CF project and is the only company in the group with a combination of novel CFTR modulators being tested ex-vivo...In Europe alone, there are more than 2,300 adult patients whose genotypes render them ineligible for approved CFTR modulators and exclude them from participating in clinical trials with this drug class. This project's proposed personalized medicine approach is paving a potential new way to develop and provide access to novel CFTR modulators for patients with the most dire need for treatment options that target the cause of the disease. Additionally, based on an individual patient's disease phenotype and not just the genetic designation, this approach could also create a new path towards more effective treatment for all people with CF."

Christiane De Boeck, work package leader at HIT-CF and former president of ECFS, added, "The inequality in access to CFTR modulators is an acute problem across Europe where 1 in 5 individuals do not have a F508del mutation...At HIT-CF Europe, we believe that novel strategies such as personalized medicine and development of new treatment options are central to addressing the inequality of access across the continent. We are thrilled with these initial results and look forward to providing additional updates."

Proteostasis Therapeutics, headquartered in Boston, Mass., is a clinical stage biopharmaceutical company developing novel small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. The firm focuses more specifically on identifying therapies that restore protein function.

Proteostasis has a market cap of about $203.0 million with approximately 51.13 million shares outstanding and a short interest around 5.7%. The stock has a 52-week price range of $0.61-5.80. PTI shares opened today at $4.30 (+$0.33, +8.31%) over yesterday's $3.97 closing price. The stock has traded today between $4.105 and $4.72 per share and at present is trading at $4.295 (+$0.325, +8.19%).

1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

{{labelSign}}  Favorites


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media


Featured Company